Clinical Guidelines

The Strategic Role of CRA AI Agents in Clinical Research

Using agentic AI to reduce clinical trial inefficiency

Share

  • 1

    Clinical trials face increasing delays due to operational inefficiencies.

  • 2

    AI is primarily targeting early drug discovery phases.

  • 3

    CRAs are overwhelmed with manual tasks and data management.

  • 4

    'White space' consumes a significant amount of drug development time.

  • 5

    Agentic AI can automate trial processes and improve efficiency.

  • 6

    The partnership between AI and CRAs is vital for faster drug approvals.

  • 7

    Current R&D spending per approved drug is around $6 billion.

  • 8

    Effective use of AI could lead to a monumental wave of new medicines.

Original Source(s)

The Strategic Role of CRA AI Agents in Clinical Research

Using agentic AI to reduce clinical trial inefficiency

  • by Andrew Mackinnon

  • March 6, 2026

  • 9 min

Related Content

Business-in-Brief: February 2026

This month’s analytical science business news: seed funding, strategic partnerships, and a surge of genomics and mass spec launches

  • March 5, 2026

  • 3 min
Shining a Light into the ADC Conjugation Black Box

A multi-year hunt for a “Goldilocks salt” paved the way for HIC-MS coupling and real-time ADC reaction monitoring

Innovations Shaping Women’s Cancer Care in 2026

As we move through 2026, new technologies and refined surgical techniques are transforming outcomes for women facing cancer diagnoses.

  • by

  • March 4, 2026

  • 6 min